GHCM
CHRS icon

Glen Harbor Capital Management’s Coherus Oncology CHRS Stock Holding History

Glen Harbor Capital Management’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$46K Hold
2,268
– – ﹤0.01% 1235
2019
Q2 		$50K Hold
2,268
– – ﹤0.01% 1250
2019
Q1 		$31K Buy
2,268
+476
+27% +$6.35K ﹤0.01% 1250
2018
Q4 		$16K Buy
+1,792
New +$20.7K ﹤0.01% 1249

Other funds holding CHRS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Glen Harbor Capital Management's CHRS Position: Q3 2019 in Review

Glen Harbor Capital Management held its Coherus Oncology (CHRS) position steady in Q3 2019 at 2,268 shares worth $46K. The position accounts for ﹤0.01% of the portfolio, ranked #1235.

Glen Harbor Capital Management first reported a position in CHRS in Q4 2018 and has held it in 4 quarters since. The position peaked at $50K in Q2 2019. 167 funds tracked by Wall St. Rank hold CHRS as of Q3 2019.

  • Glen Harbor Capital Management held 2,268 shares of Coherus Oncology worth $46K as of Q3 2019.
  • Glen Harbor Capital Management left its Coherus Oncology share count unchanged in Q3 2019.
  • Coherus Oncology made up ﹤0.01% of Glen Harbor Capital Management's portfolio in Q3 2019, its #1235 holding.
  • Glen Harbor Capital Management first reported a position in Coherus Oncology in Q4 2018 and has held it in 4 quarters since.
  • Glen Harbor Capital Management's Coherus Oncology position peaked at $50K in Q2 2019.
  • 167 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2019.

Based on Glen Harbor Capital Management's 13F filing for Q3 2019, filed 13 Nov 2019.